Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1976 1
1978 2
1979 2
1980 1
1981 1
1982 2
1984 1
1985 2
1987 2
1992 1
1993 1
1994 2
1995 6
1996 6
1997 3
1998 6
1999 2
2001 4
2002 7
2003 7
2004 6
2005 3
2006 7
2007 8
2008 5
2009 6
2010 5
2011 7
2012 6
2013 6
2014 7
2015 3
2016 8
2017 6
2018 5
2019 6
2020 3
2021 4
2022 6
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Results by year

Filters applied: . Clear all
Page 1
Huntington's Disease: New Frontiers in Therapeutics.
Pan L, Feigin A. Pan L, et al. Among authors: feigin a. Curr Neurol Neurosci Rep. 2021 Feb 14;21(3):10. doi: 10.1007/s11910-021-01093-3. Curr Neurol Neurosci Rep. 2021. PMID: 33586075 Review.
Art therapy for Parkinson's disease.
Cucca A, Di Rocco A, Acosta I, Beheshti M, Berberian M, Bertisch HC, Droby A, Ettinger T, Hudson TE, Inglese M, Jung YJ, Mania DF, Quartarone A, Rizzo JR, Sharma K, Feigin A, Biagioni MC, Ghilardi MF. Cucca A, et al. Among authors: feigin a. Parkinsonism Relat Disord. 2021 Mar;84:148-154. doi: 10.1016/j.parkreldis.2021.01.013. Epub 2021 Jan 23. Parkinsonism Relat Disord. 2021. PMID: 33526323 Free article. Clinical Trial.
Preface.
Feigin AS, Anderson KE. Feigin AS, et al. Handb Clin Neurol. 2017;144:ix. doi: 10.1016/B978-0-12-801893-4.09986-7. Handb Clin Neurol. 2017. PMID: 28947130 No abstract available.
Emerging therapeutics in Huntington's disease.
Wiggins R, Feigin A. Wiggins R, et al. Among authors: feigin a. Expert Opin Emerg Drugs. 2021 Sep;26(3):295-302. doi: 10.1080/14728214.2021.1962285. Epub 2021 Aug 6. Expert Opin Emerg Drugs. 2021. PMID: 34319843 Review.
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators. Feigin A, et al. Nat Med. 2022 Oct;28(10):2183-2193. doi: 10.1038/s41591-022-01919-8. Epub 2022 Aug 8. Nat Med. 2022. PMID: 35941373 Free PMC article. Clinical Trial.
Gene-based therapies in Parkinson's disease.
Allen PJ, Feigin A. Allen PJ, et al. Among authors: feigin a. Neurotherapeutics. 2014 Jan;11(1):60-7. doi: 10.1007/s13311-013-0233-2. Neurotherapeutics. 2014. PMID: 24129887 Free PMC article. Review.
162 results